Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.935
-0.425 (-18.01%)
At close: Aug 13, 2025, 4:00 PM
1.970
+0.035 (1.81%)
Pre-market: Aug 14, 2025, 9:01 AM EDT
Spero Therapeutics Employees
Spero Therapeutics had 32 employees as of December 31, 2024. The number of employees decreased by 14 or -30.43% compared to the previous year.
Employees
32
Change (1Y)
-14
Growth (1Y)
-30.43%
Revenue / Employee
$1,518,000
Profits / Employee
-$1,675,031
Market Cap
108.19M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SPRO News
- 1 day ago - Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 8 days ago - Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 - GlobeNewsWire
- 2 months ago - Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results - Seeking Alpha
- 2 months ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga
- 2 months ago - Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - GlobeNewsWire
- 3 months ago - Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 3 months ago - Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 - GlobeNewsWire